In the latest trading session, 0.74 million SpringWorks Therapeutics Inc (NASDAQ:SWTX) shares changed hands as the company’s beta touched 0.79. With the company’s most recent per share price at $56.90 changed hands at -$1.35 or -2.32% at last look, the market valuation stands at $4.26B. SWTX’s current price is a discount, trading about -8.96% off its 52-week high of $62.00. The share price had its 52-week low at $28.21, which suggests the last value was 50.42% up since then.
Analysts gave the SpringWorks Therapeutics Inc (SWTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SWTX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. SpringWorks Therapeutics Inc’s EPS for the current quarter is expected to be -0.74.
SpringWorks Therapeutics Inc (NASDAQ:SWTX) trade information
Instantly SWTX was in red as seen in intraday trades today. With action -0.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 57.49%, with the 5-day performance at -0.92% in the red. However, in the 30-day time frame, SpringWorks Therapeutics Inc (NASDAQ:SWTX) is 57.44% up.
The consensus price target for the stock as assigned by Wall Street analysts is 78, meaning bulls need an upside of 27.05% from its recent market value. According to analyst projections, SWTX’s forecast low is 78 with 78 as the target high. To hit the forecast high, the stock’s price needs a -37.08% plunge from its current level, while the stock would need to soar -37.08% for it to hit the projected low.
SpringWorks Therapeutics Inc (SWTX) estimates and forecasts
Year-over-year growth is forecast to reach 85.12% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 66.93M. 4 analysts are of the opinion that SpringWorks Therapeutics Inc’s revenue for the current quarter will be 75.27M. The company’s revenue for the corresponding quarters a year ago was 21.01M and 59.73M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 218.64%. The estimates for the next quarter sales put growth at 26.01%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -24.25%. The 2025 estimates are for SpringWorks Therapeutics Inc earnings to increase by 35.89%.
SpringWorks Therapeutics Inc (NASDAQ:SWTX)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.8715% or 6.54 million shares worth $246.53 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. With 3.56 shares estimated at $201.92 million under it, the former controlled 4.75% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.80% of the shares, roughly 2.1 shares worth around $118.91 million.
